Skip to content
    ARAI
    Earnings call· Jun 2026(Q2 FY26)

    Arrive AI Q2 FY26 earnings call ARAI

    Aug 13, 2026 Source

    Executive summary

    Arrive AI Inc. Q2 FY26 — Commercial Traction and Product Roadmap Expansion

    Arrive AI reported Q2 FY26 results highlighting significant commercial traction and product roadmap expansion, despite a GAAP net loss driven by non-cash expenses. The company is focused on converting its growing commercial pipeline into scaled revenue, supported by strategic financing options and a robust IP portfolio. Management emphasized the increasing market recognition of its autonomous logistics infrastructure and its plans for future product generations.

    Highlights

    5

    • Non-GAAP net loss was $4.3 million, significantly lower than the GAAP net loss of $14.1 million for Q2 FY26.

    • Cash and liquid investments increased to $5.1 million at June 30th, 2026, up from $2.1 million at December 31st, 2025.

    • Over a dozen AP3-plus Arrive Points are expected to be in stock and ready to ship by mid-September, marking a 'huge multiplier' of past deployments.

    • Expanded partnership with Hancock Regional Hospital, adding an additional Arrive Point for building-to-building movement.

    • Secured 13 international patents, mostly in Asia, and recently approved for the first patent in the European Union.

    Concerns

    3

    • GAAP net loss for Q2 FY26 was $14.1 million, including $9.7 million in non-cash expenses related to note conversion.

    • Current cash burn rate is approximately $1.1 million per month.

    • Concerns raised by investors regarding stock price, NASDAQ compliance, potential delisting, and liquidity issues.

    Guidance & targets

    4
    CategoryTargetConfidence
    AP3-plus Arrive Points availability
    More than a dozen units in stock and ready to ship
    medium materiality
    High
    AP4 product launch
    Targeted for Q1 2027
    high materiality
    High
    AvRide campus operations
    Operating on more than 20 campuses nationwide
    medium materiality
    High
    APX/AP5 prototypes
    Prototypes at the end of next year
    high materiality
    High

    Operational metrics

    12
    Net loss (non-GAAP)
    $4.3M
    Q2 FY26

    Excluding non-cash expenses, the net loss was significantly lower.

    Cash and liquid investments
    $5.1Mup from $2.1M at December 31, 2025
    June 30, 2026

    Reflects an increase in liquidity over the past six months.

    Cash burn rate
    $1.1M
    per month

    Current rate reflects deliberate investment in team, technology, and infrastructure.

    S3 registration statement capacity
    $100M
    future

    Filed during the quarter, providing future financing optionality.

    At-the-market (ATM) offering capacity
    $15M
    future

    Finalized terms for an ATM offering up to this maximum capacity.

    Equity line facility available capacity
    $19M
    future

    Retained available capacity under the previous 2025 equity line facility.

    US approved patents
    10
    current

    Covers initial IP for a strong competitive moat.

    US pending patents
    4
    current

    Additional patents pending in the US patent office.

    Ideas in hopper
    19
    current

    New ideas from engineers awaiting patent application.

    International issued patents
    13
    current

    Strong international patent presence, primarily in Asia.

    European Union approved patents
    1
    recently

    First patent approved for the EU, opening up licensing opportunities.

    Winch patent
    —
    current

    A strategic purchase that allows for a different, more organized and controlled way to handle product coming from drones.

    Industry KPIs

    3
    MetricValueDetails
    Smb b2b mixAvRide operating on more than 20 campusescampuses
    Healthcare vertical mixNexus AMR partnership, Hancock Hospital expansion, Lifespan Pharmacy and Cardon LOI
    Network reconfigurationOver a dozen AP3-plus unitsunits

    Product announcements

    3
    ProductTypeDetails
    AP3-plus Arrive Pointsexpansion
    AP4roadmap
    APX / AP5roadmap

    Deals & partnerships

    5
    Nexus AMRPartnering to deliver end-to-end autonomous solutions for customers across multiple industries.

    Nexus AMR integrates Arrive AI's products into their automation portfolio and features Arrive AI's solutions at their Innovation Center.

    Hancock Regional HospitalExpanded their network by adding an additional Arrive Point.

    Enables building-to-building movement, a significant milestone for healthcare and large campus facilities.

    DXCPartnering to bring Arrive AI's technology into large pharmaceutical manufacturing environments.

    DXC's systems integration expertise is crucial for deploying in facilities spanning 500,000 sq ft or more, including drone movement.

    Lifespan Pharmacy and CardonLetter of intent to explore an autonomous drone pharmacy delivery program.

    Early stage exploration of drone pharmacy delivery.

    AvRideAutonomous delivery partner for universities, taking over Starship Technologies' US campus operations.

    AvRide expects to operate on more than 20 campuses nationwide by end of 2026. Arrive AI is in early conversations to employ its network for unattended delivery efficiencies.

    Risks & headwinds

    3
    NASDAQ compliance and potential delistingOngoing

    Concerns raised by multiple investors regarding stock price and NASDAQ compliance.

    Mitigation: Management asserts the company is not at risk of running out of funds, citing available financing options (S3 registration, ATM offering, equity line facility) and the new CFO's capital markets background to sharpen financing paths.

    Cash burn rateOngoing

    Approximately $1.1 million per month.

    Mitigation: Management states this reflects deliberate investment in team, technology, and infrastructure to convert the commercial pipeline into scaled revenue, while prudently managing operating and investment spend.

    Non-cash expenses impacting reported net lossQ2 FY26

    $9.7 million in non-cash expenses related to the conversion of outstanding notes, leading to a GAAP net loss of $14.1 million.

    Mitigation: Management highlights the non-GAAP net loss of $4.3 million to provide a clearer picture of operational performance, indicating these are one-time accounting adjustments rather than ongoing operational cash outflows.

    What to watch in Q3 FY26

    5

    AP3-plus Arrive Points deployment

    Next quarter (Q3 FY26)
    CurrentOver a dozen units expected to be in stock and ready to ship by mid-September
    TargetConfirmation of actual deployment numbers and initial operational impact

    Why it matters

    Verifies the company's ability to execute on product availability and initial commercial rollout, crucial for scaling revenue.

    We expect to have more than a dozen AP3-plus. arrive points in stock and ready to ship by mid-September, representing our first wave of expanded availability and the solidification of our supply chain.

    Q&A highlights

    5

    How many Arrive Points are currently operating, and how does the 'over a dozen' new units relate to the 20 campuses AvRide is targeting? What are the sticking points for scaling to hundreds or thousands of units?

    The 'over a dozen' units represent a significant multiplier of past deployments, indicating vertical trajectory. AvRide's campus expansion is separate, but Arrive AI is in early talks with AvRide for potential pilot programs. The company's product roadmap (AP3 Plus, AP4, APX/AP5) is designed for progressive scaling, with supply chains for APX/AP5 targeting thousands to tens of thousands of units by end of 2027.

    “the over a dozen units that we mentioned in the earnings call represents a huge multiplier of our past deployments. So that while over a dozen isn't a huge number in the abstract, it really marks traction that we're seeing and it's a huge multiplier on what we've had deployed so far.”

    asked by Jack Codero · answered by Dan O'Toole

    2 min read5 chapters

    Detailed Narrative

    01

    Commercial Traction and Strategic Partnerships

    Arrive AI reported significant commercial traction across healthcare, manufacturing, and specialty pharmacy delivery. Key partnerships include Nexus AMR for end-to-end autonomous solutions in healthcare, DXC for pharmaceutical manufacturing environments, and a letter of intent with Lifespan Pharmacy and Cardon for drone pharmacy delivery. The company is also engaged in early-stage discussions with several Fortune 500 companies for pharmaceutical delivery. AvRide, an autonomous delivery robot partner, is expanding its campus operations, with Arrive AI exploring integration for unattended delivery efficiencies.

    02

    Product Roadmap and Scalability

    The company is expanding its product availability with over a dozen AP3-plus Arrive Points expected to ship by mid-September, representing a 'huge multiplier' of past deployments. Looking ahead, the AP4 is targeted for Q1 2027, designed to support multiple deliveries, AMR pickup/drop-off, and drone delivery. Further out, prototypes for APX (or AP5) are expected by the end of 2027, with supply chains being designed to scale to thousands and tens of thousands of units, indicating a clear long-term growth strategy.

    03

    Financial Overview and Funding Strategy

    Q2 FY26 revenue was $14,700, in line with Q1. The reported net loss was $14.1 million, but on a non-GAAP basis, excluding $9.7 million in non-cash expenses from note conversion, the net loss was $4.3 million. Cash and liquid investments increased to $5.1 million at June 30th, 2026, from $2.1 million at December 31st, 2025. The company has filed an S3 registration for up to $100 million and finalized an ATM offering for up to $15 million, alongside $19 million available from a previous equity line, providing significant financing optionality.

    04

    Intellectual Property and Patent Strategy

    Arrive AI boasts a strong IP portfolio, with 10 approved US patents and 4 more pending. Internationally, the company has 13 issued patents, primarily in Asia (India, Singapore, Australia, Japan), and recently secured its first patent in the European Union. This global patent strategy aims to establish a strong competitive moat and facilitate licensing opportunities in key international markets, with a focus on Asia and Europe.

    05

    Market Awareness and Growth Plan

    Management noted a significant uptick in inbound inquiries from large players, indicating growing market recognition for Arrive AI's role in autonomous logistics. The company's growth plan for the remainder of the year and next focuses on converting its commercial pipeline into scaled revenue, carefully allocating product deployments to best-fit partners. Marketing efforts are concentrated on a 'rifle shot approach' to enterprise accounts and early innovators, rather than broad consumer advertising.

    AI-generated summary of the company’s earnings call. Not investment advice.